Neos Therapeutics (NASDAQ:NEOS) stock price target reduced to $8.00, released a report earlier today by UBS
- Updated: March 20, 2017
Stating a potential upside of 0.08%, UBS bumped down the target of Neos Therapeutics (NASDAQ:NEOS) to $8.00
Showing a price of $7.40, Neos Therapeutics (NASDAQ:NEOS) traded -3.95% lower on the day. The last stock price is up 11.24% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has increased 0.04% over the same period. Neos Therapeutics has recorded a 50-day average of $6.03 and a two hundred day average of $6.56. Trade Volume was up over the average, with 657,823 shares of NEOS changing hands over the typical 309,570
See Chart Below
Neos Therapeutics has with a one year low of $4.85 and a one year high of $11.50 and has a market capitalization of $0.
A total of 4 equity analysts have released a ratings update on NEOS. zero brokers rating the stock a strong buy, 0 brokers rating the stock a buy, zero brokerages rating the company a hold, zero brokerages rating the stock a underperform, and finally 0 brokerages rating the stock a sell with a average stock price target of $22.50.
More About Neos Therapeutics (NASDAQ:NEOS)
Neos Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD). Its product candidates are extended-release (XR), medications in patient-friendly, orally disintegrating tablets (ODT) or liquid suspension dosage forms. Its branded product and product candidates incorporate over two of the prescribed medications for the treatment of ADHD, methylphenidate and amphetamine. Its modified-release drug delivery platform has enabled it to create extended-release ODT and liquid suspension dosage forms of the medications. It focuses on developing Adzenys XR-ODT, Cotempla XR-ODT and NT-0201.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.